Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use.
about
Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver diseaseRUCAM in Drug and Herb Induced Liver Injury: The UpdateDrug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting.Drug-induced liver injury: Do we know everything?Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: data from a national US cohort.Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era.Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease.Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Prevention and management of treatment failure to new oral hepatitis C drugs.New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs).Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?The oncologic burden of hepatitis C virus infection: A clinical perspective.Highlights of drug - and herb- induced liver injury in the literature from 2016: how best to translate new information into clinical practice?Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients.Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES.New hepatitis C therapies for special patient populations.Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report.Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens.Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis.The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.Hepatic effect of sofosbuvir and daclatasvir in thioacetamide-induced liver injury in rats
P2860
Q26752433-F642F42E-460B-49F6-A03E-42A73379839CQ26771817-F768596C-D945-4AF0-B613-42A3204FC076Q30241648-B85CE805-FF8E-4966-9677-923358E4B914Q30250096-BDBE3096-7E23-49CB-B5C1-1DADADC59356Q31160142-8D3E8C1E-657D-46E8-B467-BA9817974DCDQ33805907-CF087C9E-6946-466E-A38D-94B52DD693F5Q37748005-18CED114-A78A-4244-9C9F-B88F1B362F53Q38606004-DB43D9D9-0E1A-4B5F-B23C-C5CBBEDD4152Q38753617-6379D708-40AC-43EA-B112-01E390383930Q38811345-314A4C9C-B082-48B4-9E08-9776BAE9682FQ38826176-C4690DD2-B226-4F78-9B1B-6BE50CF71301Q38826624-FC40AA43-428C-457A-B53F-0C589E0DD95CQ39016874-BB30F451-1C29-4945-95AF-059F6122125AQ39203624-717FF881-208D-4C42-A032-6D9ADD54202AQ39418450-D4819EA8-F2E3-4BBD-9B71-4D9C31813916Q40096207-8C47473C-103A-490A-B9B6-3264A3FB3AA2Q40211318-E79A81FF-A4E6-4460-B6CE-FCCBBC1B93CFQ40489570-7AE77563-5B09-4EF9-9C04-BC376504AF37Q40899794-92482E31-B171-47B1-8E02-2C956E73650BQ41950293-48A03D52-AFE2-4914-97D0-39CF04C823F0Q49200882-DC9F633B-AF51-46A0-B60A-FEC770B0662BQ53684076-765AD69E-B3E5-4A46-987B-5FE675FBCB37Q55288229-DA470068-96DB-48AD-AE7B-1EEF8E4F511CQ57494347-68C7BB40-4A74-4189-94CB-87E0B644C5D5
P2860
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use.
@en
type
label
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use.
@en
prefLabel
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use.
@en
P2093
P1476
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use
@en
P2093
Dina Tiniakos
Graham R Foster
Jessica K Dyson
John Hutchinson
Laura Harrison
Mark A Aldersley
Olorunda Rotimi
P304
P356
10.1016/J.JHEP.2015.07.041
P577
2015-08-29T00:00:00Z